[Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients--PERMAL study subset analysis].

Debruyne, F; Boyle, P; Calais da Silva, F; Gillenwater, JG; Hamdy, FC; Perrin, P; Teillac, P; Vela-Navarrete, R; Raynaud, JP; Schulman, C

Abstract:

OBJECTIVE: To compare the efficacy of the lipido-sterolic extract of Serenoa repens, Permixon, to that of the a-blocker, tamsulosin, in the treatment of severe low urinary tract symptoms (LUTS) of benign prostatic hyperplasia (BPH). METHODS: In a 12-month, double-blind, randomized study that showed equivalent efficacy of Permixon 320 mg/day and tamsulosin 0.4 mg/day ("PERMAL study"), 685 BPH patients with IPSS > 10 had been analyzed for efficacy. Of these, the 124 patients with severe LUT...

Expand abstract

Publication status:

Published

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Debruyne, F., Boyle, P., Calais da Silva, F., Gillenwater, J. G., Hamdy, F. C., Perrin, P., Teillac, P., Vela-Navarrete, R., Raynaud, J. P., & Schulman, C. (2004). [Evaluation of the clinical benefit of Permixon and tamsulosin in severe BPH patients--PERMAL study subset analysis]. Progres En Urologie : Journal De l'Association Francaise d'Urologie Et De La Societe Francaise d'Urologie, 14(3), 326–331.

MLA Style

Debruyne, F., et al. “[Evaluation of the Clinical Benefit of Permixon and Tamsulosin in Severe BPH Patients--PERMAL Study Subset Analysis].” Progres En Urologie : Journal De l'Association Francaise d'Urologie Et De La Societe Francaise d'Urologie, vol. 14, no. 3, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2004, pp. 326–31.

Chicago Style

Debruyne, F, P Boyle, F Calais da Silva, JG Gillenwater, FC Hamdy, P Perrin, P Teillac, R Vela-Navarrete, JP Raynaud, and C Schulman. 2004. “[Evaluation of the Clinical Benefit of Permixon and Tamsulosin in Severe BPH Patients--PERMAL Study Subset Analysis].” Progres En Urologie : Journal De l'Association Francaise d'Urologie Et De La Societe Francaise d'Urologie 14 (3): 326–31.
Tweet
Print

Authors

+ Debruyne, F More by this author

Role:

Author

+ Boyle, P More by this author

Role:

Author

+ Calais da Silva, F More by this author

Role:

Author

+ Gillenwater, JG More by this author

Role:

Author

+ Hamdy, FC More by this author

Institution:

University of Oxford

Department:

Oxford, MSD, Surgical Sciences, Biomedical Research Centre

Role:

Author

Expand authors...

Bibliographic Details

Journal:: Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie
Volume:: 14
Issue:: 3
Pages:: 326-331
Publication date:: 2004-06-05
ISSN:: 1166-7087
URN:: uuid:7b59aa46-123b-48ee-ae33-413408c20c22
Source identifiers:: 120716
Local pid:: pubs:120716

Item Description

Language:: French
Keywords:: Aged

Prostatic Hyperplasia

Male

Severity of Illness Index

Humans

Serenoa

Plant Extracts

Androgen Antagonists

Adrenergic alpha-Antagonists

Middle Aged

Double-Blind Method

Sulfonamides

Terms of use

License:: Terms and Conditions of Use for Oxford University Research Archive

Views & Downloads

Metrics

If you are the owner of this record, you can report an update to it here: Report update to this record